There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Daré Bioscience (DARE – Research Report), Mereo Biopharma Group Plc (MREO – Research Report) and Arcus Biosciences (RCUS – Research Report) with bullish sentiments.
Daré Bioscience (DARE)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Daré Bioscience, with a price target of $6.00. The company’s shares closed last Tuesday at $0.31, close to its 52-week low of $0.27.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
Currently, the analyst consensus on Daré Bioscience is a Moderate Buy with an average price target of $4.00.
See today’s best-performing stocks on TipRanks >>
Mereo Biopharma Group Plc (MREO)
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Mereo Biopharma Group Plc, with a price target of $6.00. The company’s shares closed last Tuesday at $3.05.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Mereo Biopharma Group Plc has an analyst consensus of Strong Buy, with a price target consensus of $6.00.
Arcus Biosciences (RCUS)
In a report released yesterday, Kaveri Pohlman from BTIG maintained a Buy rating on Arcus Biosciences, with a price target of $70.00. The company’s shares closed last Tuesday at $15.23.
According to TipRanks.com, Pohlman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $43.00 average price target, a 179.6% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DARE:
- Daré Bioscience Secures Funding and Forges Royalty Agreements
- Dare Bioscience announces it will receive payment of $1M under grant agreement
- Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
- Biotech Alert: Searches spiking for these stocks today
- Dare Bioscience downgraded to Hold from Buy at Brookline
